Cerevast raises $10 million for its new therapeutic headframe device

Redmond biotech company Cerevast Therapeutics has raised $10 million as it continues to test a headset it hopes will one day be used to treat stroke patients. That brings the company’s total fundraising up to nearly $32.5 million, according to company CEO Bradford Zakes. The company was formed in 2009 and announced earlier this year it had passed its first interim safety analysis as it rolls out trials of its “Clotburst ER” device. 

Cerevast Therapeutics, a 5-year-old Redmond company that’s developing a novel approach for treating stroke patients with ultrasound, has raised $10 million in fresh funding, according to a filing with the SEC. Led by Bradford Zakes, Cerevast was formed in 2009 after the company purchased the assets of ImaRx Therapeutics. Zakes previously worked at ICOS and Glaxo. Earlier this year, the company said that its device passed four independent safety reviews, and that it continued to move forward with clinical studies. Here’s how the company describes the ClotBuster device, which attaches to a patient’s head.